Status: Not yet recruiting
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
To find the best method of administering NK cells in patients with recurrent glioblastoma.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 12, 2026Locations: 1
Eligibility criteria
Male or female subjects aged ≥ 18 years. [+11]
Has received prior interstitial brachytherapy, implanted chemotherapy, or therap... [+21]